Drugs / tipronone
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| — | NCT07152860 Comparator | Dec 2025 → Dec 2026 expected | chronic atrophic gastritis | Yi Liang | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tipronone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07152860 ↗ |
| Known as | Svi-Shu | “Patients in the Simple tipronone capsules group(basic treatment group) will receive only conventional basic drug therapy. They will be given Svi-Shu (tipronone capsules) (Eisai...” NCT07152860 ↗ |
| Route | Oral | “Patients will also be administered SviShu (tipronone capsules) (Wei Cai Pharmaceutical Co., Ltd., National Drug Approval Number H20093656, dosage: 50 mg) orally, one capsule at...” NCT07152860 ↗ |